Loading people...
Kabeer Aziz is a Co-Founder and Partner at Adjuvant Capital in New York, where he manages investments from the firm's $300 million global health technology fund. Before establishing Adjuvant, he served as a Senior Associate at the Global Health Investment Fund from 2015 to 2018 and worked as an Associate at Metalmark Capital focusing on healthcare private equity. He began his career advising on biopharmaceutical mergers and acquisitions as an Analyst at Greenhill & Co., after earning a Bachelor of Science from the NYU Stern School of Business. Aziz has led investments in several life sciences companies, including Themis Bioscience, which was acquired by Merck, and currently holds board seats at MinervaX and AN2 Therapeutics. His investment strategy centers on funding vaccines, therapeutics, and diagnostics to address historically overlooked medical challenges in underserved markets.
Kabeer Aziz is a distinguished Principal at Adjuvant Capital, a leading global health venture fund. In his role, Kabeer is instrumental in advancing Adjuvant Capital's mission to invest in groundbreaking life science companies that offer market-based solutions to some of the world's most pressing public health issues. His expertise lies in identifying promising ventures that not only demonstrate strong commercial viability but also possess the potential for profound societal impact, particularly in low- and middle-income countries.
At Adjuvant Capital, Kabeer Aziz plays a crucial role in the entire investment lifecycle, from deal sourcing and rigorous due diligence to portfolio management and strategic support for investee companies. He works closely with entrepreneurs and scientific innovators, leveraging his deep understanding of both the financial landscape and the global health ecosystem to help scale solutions in areas such as infectious diseases, maternal and child health, and neglected tropical diseases. His commitment aligns perfectly with Adjuvant Capital's dual mandate of achieving competitive financial returns alongside measurable public health impact.
Kabeer's career background reflects a strong foundation in finance and a dedicated focus on healthcare and impact investing. Prior to joining Adjuvant Capital, his experience likely encompassed roles that honed his analytical skills and strategic thinking within complex market environments. This background provides him with a unique perspective, enabling him to evaluate opportunities through both a commercial lens and a public health imperative. His contributions are vital in shaping Adjuvant Capital's investment strategy and ensuring the fund remains at the forefront of global health innovation.
While specific individual investments are often part of a fund's collective effort, Kabeer Aziz contributes significantly to Adjuvant Capital's overall portfolio success. He helps to identify and nurture companies that are developing novel vaccines, diagnostics, therapeutics, and other health technologies designed to be accessible and affordable for those who need them most. His work directly supports the growth of companies poised to make a tangible difference in global health outcomes, reinforcing Adjuvant Capital's position as a pivotal player in the impact investing space.
Kabeer Aziz is a Principal at Adjuvant Capital, a global health venture fund. He specializes in identifying and supporting life science companies that develop market-based solutions to critical public health challenges worldwide, focusing on both financial returns and social impact.
Kabeer Aziz, through Adjuvant Capital, invests in innovative life science companies. These investments focus on developing solutions for global health challenges, including vaccines, diagnostics, and therapeutics, particularly for underserved populations and in areas like infectious diseases and maternal health.
Kabeer Aziz works as a Principal at Adjuvant Capital. Adjuvant Capital is a global health venture fund dedicated to investing in companies that address significant public health needs with market-based solutions.
